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Summary
Objective:	Patients	with	mutations	of	neurokinin	B	(NKB)	and	its	receptor	show	hypog-
onadotrophic	hypogonadism,	but	there	is	little	evidence	for	the	importance	of	this	path-
way	in	reproductive	function	in	normal	men,	or	its	functional	hierarchy	with	kisspeptin.
Design:	An	open	label	study	wherein	men	(n	=	6)	were	administered	the	NK3R	antago-
nist	MLE4901	40	mg	orally	twice	a	day	for	7	days.	Kisspeptin-	10	(0.3	μg/kg	iv	bolus)	
was	given	before	and	on	day	7	of	NK3R	antagonist	treatment.
Patients:	Subjects	were	healthy	men.
Measurements:	Reproductive	hormones	were	measured	before	and	during	the	NK3R	
antagonist	administration,	including	frequent	sampling	on	two	occasions	for	analysis	
of	pulsatile	LH	secretion.
Results:	LH,	FSH	and	testosterone	secretion	were	decreased	during	NK3R	antagonist	
administration.	LH	showed	a	biphasic	response,	being	reduced	after	24	hours	of	treat-
ment	(4.5	±	0.6	IU/L	pretreatment	to	1.7	±	0.2	IU/L,	P	<	.05),	with	partial	recovery	there-
after,	but	it	was	again	decreased	on	day	7	(2.5	±	0.6	IU/L,	P	<	.05	vs	pretreatment).	FSH	
secretion	was	also	suppressed,	with	a	similar	temporal	pattern	to	that	of	LH.	Testosterone	
secretion	was	decreased	 from	24	hours	 (18.4	±	1.6	pretreatment	vs	5.6	±	1.5	nmol/L,	
P	<	.01)	and	remained	suppressed	throughout	the	treatment	period.	Analysis	of	LH	pul-
satility	showed	that	both	basal	and	pulsatile	LH	secretion	were	markedly	suppressed	but	
there	was	no	detected	change	in	LH	pulse	frequency.	Kisspeptin-	10	stimulated	LH	se-
cretion,	with	similar	responses	before	and	during	NK3R	antagonist	administration.
Conclusions:	These	data	demonstrate	a	central	role	for	NKB/NK3R	in	the	physiologi-
cal	regulation	of	reproductive	function	in	men,	and	that	this	is	functionally	upstream	of	
kisspeptin-	mediated	GnRH	secretion.
K E Y W O R D S
GnRH	pulsatility,	gonadotrophins,	kisspeptin,	neurokinin	B,	testosterone
1  | INTRODUCTION
Kisspeptin	 and	neurokinin	B	 (NKB)	 are	hypothalamic	neuropeptides	
now	 recognized	 to	 be	 key	 regulators	 of	 GnRH	 secretion	 and	 thus	
central	 to	 the	 control	 of	 the	 human	 hypothalamo-	pituitary-	gonadal	
(HPG)	axis.1	Men	and	women	with	loss-	of-	function	mutations	in	kis-
speptin,	neurokinin	B	or	their	cognate	receptors	(KISS1R	and	NK3R)	
show	 reduced	 GnRH	 secretion	 and	 hypogonadotropic	 pubertal	
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delay,2-5	whilst	activating	mutations	in	the	kisspeptin	receptor	are	as-
sociated	with	precocious	puberty.6
Whilst	 kisspeptin	 potently	 stimulates	 gonadotropin	 secretion	
7-11	 and	 increases	 LH	 pulse	 frequency	 in	 men,9	 the	 effects	 of	 ex-
ogenous	 NKB	 administration	 are	 unclear.	 In	 animal	 studies,	 both	
stimulatory	 and	 inhibitory	 actions	 of	 NKB	 on	 LH	 secretion	 have	
been	observed12-14	whilst	it	had	no	effect	on	reproductive	hormone	
concentrations	or	LH	pulsatility	when	infused	for	8	hours	to	healthy	
men and women.15	Administration	of	the	NK3R	antagonist	ESN364	
to	normal	men	suppressed	LH	and	testosterone	but	not	FSH	secre-
tion.16	However,	the	effect	on	LH	lasted	only	few	hours	with	recovery	
to	baseline	within	24	hours.16	Antagonism	of	NK3R	has	been	shown	
to	decrease	LH	secretion	and	reduce	the	frequency	of	LH	pulses	 in	
women	with	PCOS17	and	in	gonadectomized	animals,18,19	indicating	a	
role	for	NKB-	NK3R	signalling	in	the	regulation	of	pulsatile	GnRH	and	
thus	LH	secretion.
Kisspeptin	 and	NKB	are	 co-	expressed	by	 some	neurones	within	
the	hypothalamus,	in	humans	and	other	species.	These	neurones	can	
also	 co-	express	 the	 opioid	 dynorphin	 and	 thus	 have	 been	 termed	
KNDy	neurones.20	The	interaction	and	functional	hierarchy	between	
kisspeptin	 and	 neurokinin	 B	 are	 inferred	 from	 observations	 from	
preclinical	 and	clinical	 studies.	Thus	 in	animal	models,	Kissr1 knock-
out	 mice	 were	 unable	 to	 show	 a	 stimulatory	 effect	 of	 the	 NK3R	
agonist	senktide	on	LH	secretion,21	and	in	juvenile	male	monkeys,	kis-
speptin-	10	 stimulated	 LH	 secretion	 after	 desensitization	with	 senk-
tide	infusion.14	These	results	suggest	the	action	of	NKB	is	upstream	
of	kisspeptin.	This	is	supported	by	studies	in	patients	with	inactivating	
genetic	defects	in	NKB	(TAC3)	and	its	NK3	receptor	(TAC3R),	showing	
slow	GnRH	secretion	as	inferred	from	low	LH	secretion,	in	whom	kis-
speptin-	10	 increased	LH	pulse	frequency.22	Women	treated	with	an	
NK3R	antagonist	in	a	model	of	the	mid-	cycle	LH	surge	showed	largely	
preserved	 LH	 response	 to	 kisspeptin	 administration,	 although	 there	
were	effects	on	timing	and	duration,	and	the	relationship	to	circulating	
oestradiol	concentrations	was	lost,23	providing	evidence	that	neuroki-
nin	B	is	functionally	upstream	of	kisspeptin	in	the	regulation	of	GnRH	
secretion	in	healthy	women.
We,	 therefore,	 sought	 to	 determine	whether	NKB	 has	 a	 physi-
ological	 role	 in	 the	 regulation	of	 the	male	 reproductive	 axis	by	 the	
administration	of	 the	specific	NK3R	antagonist	MLE4901,	with	de-
tailed	 analysis	 of	 potential	 effects	 on	 GnRH/LH	 pulsatility,	 and	 to	
explore	the	hierarchy	between	NKB	and	kisspeptin	in	the	control	of	
this	pathway.
2  | MATERIALS AND METHODS
2.1 | Study subjects
Six	 healthy	men,	 aged	 23-	39	years	 were	 recruited	 to	 this	 study;	 all	
volunteers	provided	informed	written	consent	and	the	study	received	
Ethics	Committee	approval.	Subjects	had	normal	physical	examination	
and	 serum	LH,	 FSH	and	 testosterone	 concentrations,	 and	 full	 blood	
count,	renal	function,	electrolytes,	liver	function	and	electrocardiogram	
were	within	normal	limits.
2.2 | Study drugs
The	 NK3R	 antagonist	 MLE4901	 (previously	 known	 as	 AZD4901,	
kindly	 provided	 by	 AstraZeneca)	 was	 administered	 orally	 at	 40	mg	
twice	daily.	It	has	been	shown	to	completely	block	neurokinin	B	agonist	
senktide	 induced	calcium	influx	 in	human	NK3R	expressing	Chinese	
hamster	ovary	cells	with	high	selectivity.24	This	dose	of	MLE4901	re-
duced	LH	secretion	and	pulse	 frequency	 in	normal	women23 and in 
women	with	Polycystic	Ovary	Syndrome.17	Kisspeptin-	10	was	admin-
istered	by	an	intravenous	bolus	at	0.3	μg/kg	as	previously	described,9 
with	the	dose	chosen	as	the	lowest	that	caused	maximal	stimulation	
in	LH	secretion.9
2.3 | Protocol
2.3.1 | Investigation of the effect of NK3R  
antagonism on gonadotropin and testosterone  
secretion
A	 schematic	 representation	 of	 the	 protocol	 is	 shown	 in	 Figure	1.	
Volunteers	were	administered	the	NK3R	antagonist	for	7	days.	Single	
time	 point	 daily	 peripheral	 venous	 blood	was	 sampled	 for	 LH,	 FSH	
and	 testosterone	measurement	 between	 08.00	 and	 10.00	hours	 at	
24	hours	before	treatment	started	(day	−1)	and	on	days	2,	4,	6	and	7	
of	NK3R	antagonist	administration.	During	treatment,	the	daily	blood	
sampling	was	performed	immediately	prior	to	the	next	dose	of	NK3R	
antagonist,	that	is	12	hours	after	the	previous	dose.
2.3.2 | Investigation of the effect of NK3R 
antagonist on LH pulsatility
On	day	−1	and	on	the	last	day	of	NK3R	antagonist	administration	(day	
7),	 volunteers	attended	our	clinical	 research	 facility	 for	8	hours.	On	
F IGURE  1 Study	protocol.	Six	healthy	men	were	administered	
the	NK3R	antagonist	MLE4901	orally	for	7	days.	LH,	FSH	and	
testosterone	were	measured	on	days	−1,	2,	4,	6	and	7	during	the	
study.	LH	pulsatility	was	assessed	for	6	hours	on	day	−1	and	on	day	
7,	the	last	day	of	NK3R	antagonist	treatment.	Kisspeptin	(KP)-	10	was	
administered	by	intravenous	bolus	at	6	hours	with	further	frequent	
blood	sampling	for	2	hours	on	day	−1	and	day	7
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day	7,	 volunteers	 took	 the	NK3R	 antagonist	within	 an	hour	 before	
starting	 the	 pulsatility	 assessment	 blood	 sampling.	 All	 visits	 com-
menced	 between	 08.00	 and	 09.00	hours.	 Blood	 samples	 were	 col-
lected	 via	 an	 indwelling	 intravenous	 cannula	 at	 10-	minute	 intervals	
for	6	hours	for	assessment	of	LH	pulsatility.
2.3.3 | Establishment of the hierarchy between 
kisspeptin and neurokinin B in the regulation of 
LH secretion
Kisspeptin-	10	was	administered	at	6	hours	of	the	pulsatility	study	de-
scribed	above,	with	blood	sampling	every	10	minutes	for	2	hours	after	
administration.
Safety	blood	tests	including	full	blood	count,	renal	function,	electro-
lytes	and	liver	function	were	checked	before	commencing	MLE4901,	at	
the	end	of	7-	day	treatment	and	2-	3	weeks	later.	Post-	treatment	testos-
terone	concentrations	were	measured	2	weeks	after	treatment.
2.4 | Hormone assays
Blood	samples	were	centrifuged	and	serum	frozen	at	−20°C	or	below	
until	 analysis.	 LH	 and	 FSH	 were	 measured	 by	 ELISA	 as	 previously	
described.9	 Testosterone	 was	measured	 by	 liquid	 chromatography-	
tandem	mass	spectrometry.	LH	pulsatility	was	assessed	by	deconvo-
lution	analysis	on	blinded	data	with	ApEn	quantified	as	a	measure	of	
secretory	regularity.25
2.5 | Statistical analysis
Mean	LH,	FSH	and	testosterone	concentrations	over	time	were	com-
pared	 using	 one-	way	 analysis	 of	 variance	 (ANOVA)	 with	 repeated	
measures	 followed	by	Bonferroni’s	post	hoc	 correction	 for	multiple	
comparisons.	Area	under	the	curve	(AUC)	of	LH	during	frequent	sam-
pling	was	determined	by	trapezoid	integration	on	day	−1	(control)	and	
on	day	7	of	NK3R	antagonist	administration,	and	the	change	in	AUC	
LH	during	one	hour	prekisspeptin-	10	injection	and	for	the	2	consecu-
tive	hours	 thereafter	was	calculated.	Comparisons	across	both	 time	
and	 between	 treatments	were	 performed	 using	 repeated	measures	
two-	way	 ANOVA	with	 Bonferroni’s	 multiple	 comparisons	 post	 hoc	
analysis.	 Paired	 Student’s	 t	 test	 (for	 parametric	 data)	 or	 Wilcoxon	
matched-	pairs	 signed	 rank	 test	 (for	 nonparametric	 data)	were	 used	
to	assess	changes	 in	measures	of	LH	pulsatility.	Data	are	presented	
as	mean	±	SEM.
2.6 | Ethical approval
The	study	protocol	was	approved	by	South	East	Scotland	Research	
Ethics	Committee	(Ref:	09/S1101/67).
3  | RESULTS
3.1 | NK3R antagonist decreases gonadotropin and 
testosterone secretion
LH	 secretion	based	on	daily	 LH	values	decreased	during	NK3R	an-
tagonist	 administration	 (P	<	.03),	with	 a	 biphasic	 response:	 LH	 con-
centrations	 were	 significantly	 reduced	 after	 24	hours	 of	 treatment	
(4.5	±	0.6	IU/L	on	day	−1	to	1.7	±	0.2	IU/L	on	day	2,	P	<	.05)	and	then	
recovered	(4.2	±	0.7	IU/L	on	day	4	and	3.7	±	0.7	IU/L	on	day	6)	but	
were	 again	 decreased	 on	 day	 7	 (2.5	±	0.6	IU/L	 vs	 day	 −1,	 P	<	.05)	
(Figure	2A).	To	detect	subtle	changes	in	hormone	secretion	over	time	
potentially	 overlooked	 by	 performing	 single	 time	 blood	 sampling,	 a	
F IGURE  2 LH,	FSH	and	testosterone	
response	to	administration	of	NK3R	
antagonist	in	healthy	men	(n	=	6).	(A)	
Mean	of	daily	LH	concentrations	during	
7	days	of	NK3R	antagonist	treatment	and	
(B)	LH	AUC	during	6	hours	of	10-	minute	
LH	sampling	on	day-	1	and	on	day	7	of	
NK3R	antagonist	administration.	Mean	
FSH	(C)	and	testosterone	(D)	response	
to	NK3R	antagonist	administration.	Data	
are	presented	as	mean	±	SEM.	*P < .05; 
**P	<	.01;	***P	<	.001;	****P < .0001  
vs	day	−1
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more	detailed	analysis	of	LH	secretion	every	10	minutes	for	6	hours	
post-	NK3R	antagonist	dose	on	day	7	of	treatment	showed	a	decrease	
in	LH	AUC	throughout	the	6	hours	post-	treatment	compared	to	day	
−1	(16.8	±	2.7	vs	8.7	±	1.5	IU/L	over	6	hours	with	NK3Ra,	P	=	.0007,	
Figure	2B).
FSH	secretion	was	also	 suppressed	during	NK3R	antagonist	 ad-
ministration	 (P	=	.001),	 being	 significantly	 lower	 after	 24	hours	 of	
treatment	 (3.6	±	0.3	 vs	 2.4	±	0.4	IU/L,	 P	<	.001)	 (Figure	2C).	 FSH	
showed	 a	 comparable	 pattern	 to	 changes	 in	 LH	 over	 the	 following	
days,	being	significantly	 lower	than	day	−1	on	days	2,	4	and	7	(each	
P	<	.05	vs	day	−1)	but	not	on	day	6	of	NK3R	antagonist	administration.
Testosterone	secretion	declined	rapidly	in	response	to	NK3R	an-
tagonist	 at	24	hours	 (18.4	±	1.6	day	−1	vs	5.6	±	1.5	nmol/L,	P	<	.01)	
but	in	contrast	to	LH,	was	consistently	suppressed	for	the	remainder	of	
the	treatment	period	(P	<	.05	on	days	4,	6	and	7	vs	day	−1)	(Figure	2D).	
Serum	 testosterone	 recovered	 to	pretreatment	 concentrations	 in	 all	
subjects	2	weeks	later	(19.8	±	2.0	nmol/L).
3.2 | Effect of NK3R antagonist on pulsatile LH 
secretion in men
The	 characteristics	 of	 the	 pulsatile	 secretion	 of	 LH	 were	 deter-
mined	 before	 and	 after	 7	days	 of	 NK3R	 antagonist	 treatment.	 The	
LH	pulse	profile	from	all	individual	subjects	is	shown	in	Figure	3.	LH	
pulse	frequency	was	unchanged	by	NK3R	antagonist	(0.50	±	0.09	vs	
0.47	±	0.07	 pulses/hour,	 ns)	 (Figure	4A).	 However,	 consistent	 with	
F IGURE  3 LH	profiles	sampled	at	
10-	minute	intervals	from	6	individual	
subjects	on	control	day	−1	(black circles)	
and	on	day	7	of	NK3Ra	administration	
(open	circles).	Arrows	indicate	LH	pulses	
detected	by	blinded	deconvolution	with	
(open	arrows)	and	without	(black	arrows)	
NK3R	antagonist	treatment
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the	overall	suppression	of	LH	secretion	seen	 in	the	daily	time	point	
analysis,	other	parameters	of	LH	secretion	were	reduced.	Both	basal	
(nonpulsatile)	 and	 pulsatile	 mass	 of	 LH	 secretion	 were	 lower	 with	
NK3R	antagonist	treatment	compared	with	day	−1	(Figure	4B-	C,	both	
P	=	.02).	The	secretory	mass	of	LH	per	pulse	(Figure	4D)	was	not	sig-
nificantly	 changed	 (P	<	.09).	NK3R	antagonist	 increased	 the	orderli-
ness	of	the	LH	secretion	pattern	as	assessed	by	approximate	entropy	
(ApEn)	(P	=	.02;	Figure	4E).
3.3 | NK3R antagonist does not reduce kisspeptin- 
induced LH secretion
To	 assess	 the	 hierarchical	 interaction	 between	 kisspeptin	 and	 neu-
rokinin	 B	 in	 the	 regulation	 of	 LH	 secretion	 in	men,	 an	 intravenous	
bolus	 injection	 of	 kisspeptin-	10	 was	 administered	 after	 6	hours	 of	
blood	 sampling	on	day	−1	and	on	day	7	of	NK3R	antagonist	 treat-
ment	(Figure	5).	Kisspeptin-	10	elicited	a	rapid	increase	in	LH	concen-
tration	(3.0	±	0.6	at	6	hours	vs	4.8	±	0.5	IU/L	at	7	hours,	P < .05 and 
AUC	LH	2.7	±	0.4	at	6	hours	vs	5.2	±	0.5	IU/L	hour	at	7	hours,	P < .01; 
Figure	5A-	B).	The	 stimulation	of	LH	secretion	by	kisspeptin-	10	was	
maintained	 in	the	presence	of	NK3R	antagonist	 (mean	LH	and	AUC	
LH	for	kisspeptin-	10+NKB	antagonist:	at	6	hours	vs	at	7	and	8	hours,	
both	 P	<	.01;	 Figure	5A-	B),	 and	 stimulated	 LH	 concentrations	 were	
similar	to	those	after	kisspeptin-	10	alone	(AUC	LH	at	7	and	8	hours	
kisspeptin-	10:	5.2	±	0.5	and	3.9	±	0.4	vs	5.2	±	0.7	and	4.0	±	0.6	IU/L	
hour	with	NK3R	antagonist,	ns).	However,	calculation	of	the	LH	re-
sponse	to	kisspeptin-	10	as	ΔAUC	over	the	2	hours	following	admin-
istration	 suggested	 an	 enhanced	 response	 during	 NK3R	 antagonist	
treatment	 (kisspeptin-	10	 alone	ΔAUC	 LH	 7	 and	 8	hours:	 2.5	±	0.2	
and	1.2	±	0.2,	 vs	 kisspeptin-	10	with	NK3R	antagonist	3.8	±	0.5	 and	
2.5	±	0.4,	both	P	<	.05;	Figure	5C)	reflecting	the	lower	LH	concentra-
tions	with	the	NK3R	antagonist	at	the	time	of	kisspeptin	administra-
tion	with	similar	LH	concentrations	after	administration	of	kisspeptin	
with	and	without	the	NK3R	antagonist.
3.4 | Tolerability and safety
MLE4901	treatment	was	well	tolerated.	One	man	reported	reduced	
libido	whist	on	NK3R	antagonist	and	this	recovered	after	the	comple-
tion	of	the	study.	Haematology	and	biochemistry	safety	parameters	
remained	stable	in	all	subjects	throughout	the	study	period.
4  | DISCUSSION
The	present	study	investigated	the	role	of	neurokinin	B	in	the	control	
of	the	reproductive	axis	in	healthy	men	and	its	interaction	with	kiss-
peptin	in	the	regulation	of	GnRH	secretion,	using	LH	as	a	surrogate.	
F IGURE  4 Analysis	of	6	hour	LH	secretory	pattern	on	day	7	of	NK3R	antagonist	treatment	compared	to	control	day	−1	in	healthy	men.	
Mean	LH	pulse	frequency	(A),	basal	(nonpulsatile)	LH	secretion	(B),	pulsatile	LH	secretion	(C),	LH	secretory	mass	per	pulse	(D)	and	the	
relative	orderliness/regularity	of	LH	secretory	pattern	(E)	on	day	7	of	NK3R	antagonist	treatment	compared	to	day	−1.	Data	are	presented	as	
mean	±	SEM.	*P	=	.02
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Pharmacological	blockade	of	NKB-	NK3R	signalling	caused	a	rapid	and	
marked	 decrease	 in	 LH,	 FSH	 and	 testosterone	 secretion.	However,	
the	stimulatory	LH	response	to	kisspeptin	after	7	days	of	NK3R	antag-
onist	was	maintained.	NK3R	antagonism	did	not	affect	the	frequency	
of	LH	pulses	in	men,	but	other	aspects	of	the	pulsatile	nature	of	LH	
secretion	were	markedly	reduced.	These	data	provide	novel	evidence	
that	NKB	is	a	major	regulator	of	the	physiological	regulation	of	GnRH/
LH	and	testosterone	secretion	in	men.	They	also	support	a	predomi-
nantly	hierarchical	relationship	whereby	central	action	of	neurokinin	B	
is	proximal	to	kisspeptin	in	the	modulation	of	GnRH/LH	secretion,	as	
previously	indicated	in	nonhuman	primates,14	in	men	with	NKB/NK3R	
mutations22	and	in	healthy	women.23
These	data	demonstrate	that	in	men,	NK3R	antagonist	administra-
tion	decreased	LH	secretion	in	a	biphasic	pattern,	with	a	marked	reduc-
tion	after	24	hours	administration	(on	day	2),	and	on	day	7.	Consistent	
with	this	being	by	suppression	of	GnRH	secretion,	NK3R	antagonist	
also	lowered	FSH	concentrations	on	days	2,	4	and	7	of	treatment,	al-
beit	to	a	lesser	extent	than	LH	secretion.	NK3R	antagonists	have	been	
reported	to	suppress	LH	secretion	in	ovariectomized	ewes	(MRK-	08)	
and	castrate	monkeys	 (ESN364)18,19	but	with	only	a	transient	effect	
in	normal	men	 (ESN364)16	without	 suppression	of	FSH	secretion	 in	
either	men16	or	castrate	monkeys.18	This	may	reflect	the	greater	effect	
on	LH	(and	by	inference	GnRH)	observed	with	MLE4901	at	40	mg	BD	
than	with	the	other	antagonists	investigated.
Sustained	 suppression	 of	 testosterone	 secretion	was	 observed	
throughout	 the	 7	days	 of	 treatment.	 Previously	 administration	 of	
this	NK3R	antagonist,	MLE4901,	reduced	both	LH	and	testosterone	
secretion	in	women	with	PCOS	after	7	days.17	The	simultaneous	de-
crease	in	serum	LH	and	testosterone	concentrations	within	24	hours	
of	treatment	suggests	a	central	role	of	neurokinin	B	in	the	regulation	
of	GnRH/LH	secretion,	which	is	further	supported	by	changes	in	the	
pattern	of	LH	pulsatility.	 It	 is	possible	 that	 recovery	of	 suppressed	
LH	 secretion	whilst	 testosterone	 levels	 remain	 low	 on	 days	 4	 and	
6	may	 indicate	 a	 direct	 gonadal	 effect	 of	 the	NK3R	 antagonist,	 as	
NKB-NK3R	mRNA	has	been	detected	 in	human	granulosa	cells.26,27 
However,	NKB-NK3R	mRNA	has	not	been	reported	in	human	testis.	It	
is,	however,	plausible	that	the	initial	fall	in	testosterone	results	in	re-
duced	negative	feedback	with	a	secondary	recovery	in	LH	secretion,	
although	 caution	 must	 be	 taken	 when	 interpreting	 those	 findings	
given	that	once	only	daily	blood	sampling	may	miss	subtle	changes	in	
hormone	secretion	especially	when	there	are	relatively	rapid	changes	
in	 steroid	 feedback	 and	 the	 pathways	 that	mediate	 that	 feedback	
are	 likely	 to	 be	 impacted	 by	 this	 drug.	Nevertheless,	 analysis	 over	
6	hours	after	dosing	on	day	7	showed	consistent	suppression	of	LH	
suggesting	that	suppression	would	persist	with	chronic	antagonism	
of	 NKB-	NK3R	 signalling.	 FSH	 secretion	 is	 less	 sensitive	 to	 rapid	
changes	in	GnRH	secretion,	which	may	account	for	the	slightly	differ-
ent	profile	of	the	FSH	response	to	NK3R	antagonism	over	the	7	days	
of	treatment.
The	present	study	has	shown	that	in	normal	men,	NK3R	antago-
nist	administration	markedly	reduced	both	basal	 (ie	nonpulsatile)	LH	
secretion	and	the	total	amount	of	LH	secreted	in	pulses,	contributing	
to	overall	lower	serum	LH	concentrations.	The	regularity	of	the	LH	se-
cretory	pattern	and	by	inference	GnRH	secretion,	showed	greater	or-
derliness,	as	indicated	by	reduced	ApEn.	NK3R	antagonist	did	not	alter	
the	 frequency	of	LH	pulses,	although	 the	ability	 to	detect	a	change	
in	LH	pulse	frequency	may	have	been	limited	by	the	small	number	of	
men	studied	here	and	the	limited	duration	of	frequent	sampling.	This	
contrasts	with	data	from	administration	of	the	same	NK3R	antagonist	
to	women	with	PCOS17	and	to	normal	women	in	a	model	of	the	LH	
F IGURE  5 LH	response	to	kisspeptin-	10	injection	with	and	
without	NK3R	antagonist	pretreatment	in	healthy	men.	(A)	Mean	
LH	concentrations	from	5	to	8	hours	of	frequent	sampling	following	
kisspeptin-	10	administration	at	hour	6;	(B)	AUC	LH	and	(C)	ΔAUC	LH	
were	compared	over	one	hour	before	kisspeptin-	10	administration	
(hour	6),	with	2	hours	postkisspeptin-	10	administration	(hours	7	and	
8),	with	(day	7)	and	without	(day	−1)	NK3R	antagonist	pretreatment	
during	frequent	blood	sampling	for	LH	every	10	minutes.	Data	are	
presented	as	mean	±	SEM.	*P	<	.05;	**P	<	.01;	****P < .0001
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surge23	 and	 to	 administration	 of	 different	NK3R	 antagonists	 (MRK-	
08	and	ESN364)	to	ovariectomized	ewes,18,19	where	reductions	in	LH	
pulse	frequency	were	demonstrated.	This	may,	however,	reflect	sexual	
dimorphism	in	that	changes	in	the	frequency	of	LH	pulses	are	not	seen	
in	male	reproduction,28	unlike	the	changes	in	LH	pulse	frequency	that	
characterize	(but	are	not	essential	for)	the	normal	menstrual	cycle.29,30 
Sexual	dimorphism	is	well	recognized	in	the	kisspeptin-	induced	LH	re-
sponse,	with	a	marked	increase	in	LH	in	men	but	a	variable	response	in	
women	dependent	on	the	sex	steroid	milieu.31,32	The	female	hypothal-
amus	has	significantly	more	kisspeptin	cell	bodies	and	fibres	compared	
to	men,33	and	there	is	a	greater	abundance	of	neurokinin	B-	expressing	
neurones	 in	 ewes	 than	 rams,34	 indicating	 gender	 differences	 in	 the	
NKB-	kisspeptin	pathway.	Testosterone	is	also	a	regulator	of	LH	pulse	
frequency	in	men,35	thus	the	fall	in	serum	testosterone	is	likely	to	have	
counteracted	any	suppressive	effect	of	NK3R	antagonism	on	LH	pulse	
frequency.	Nevertheless,	the	changes	in	LH	secretion	induced	by	the	
NK3R	antagonist	in	this	study,	in	concordance	with	a	stimulatory	ac-
tion	of	neurokinin	B	and	an	inhibitory	action	of	NK3R	antagonist	on	
LH	pulses	in	animal	studies,18,19	support	the	notion	that	neurokinin	B	
acts	centrally	to	modulate	pulsatile	GnRH	secretion	in	men	and	that	
there	are	complex	neurokinin	B/kisspeptin	interactions	that	result	in	
the	characteristics	of	the	pulsatile	secretion	of	GnRH	and	thus	LH.
Kisspeptin-	10	stimulated	LH	secretion	in	the	presence	of	NK3R	an-
tagonist	in	normal	men.	This	supports	findings	from	animal	and	human	
studies,	 in	 particular	 the	 demonstration	 that	 kisspeptin-	10	 infusion	
restored	 pulsatile	 LH	 secretion	 in	men	 and	women	with	 inactivating	
mutations	in	neurokinin	B	pathway22 and in normal women in a model 
of	 the	mid-	cycle	LH	 surge,23	 that	neurokinin	B	 signalling	 is	 function-
ally	upstream	of	kisspeptin.	There	was	a	greater	change	in	LH	secretion	
in	response	to	kisspeptin-	10	in	the	presence	of	the	NK3R	antagonist,	
but	this	is	likely	to	reflect	the	lower	basal	LH	concentrations	following	
7	days	of	NK3R	antagonist	administration.	There	was	no	difference	in	
mean	 LH	 levels	 after	 kisspeptin-	10	 administration	 alone	or	 following	
NK3R	antagonist	 treatment.	NKB	may	modulate	kisspeptin	action	by	
altering	the	sensitivity	of	GnRH	neurones	to	the	latter	and/or	by	acting	
on	GnRH	terminals	enhancing,	either	synergistically	or	additively,	kiss-
peptin	effects.	Although	NKB/Kp	immunoreactive	terminals	are	in	close	
apposition	to	GnRH	terminals	in	the	median	eminence,36	no	NK3R	ex-
pression	on	GnRH	neurones	has	been	showed	in	mice	and	ewes.37,38 
Direct	action	of	NKB	on	GnRH	neurones	therefore	seems	unlikely.
Conversely,	co-	infusion	of	neurokinin	B	itself	and	kisspeptin-	54	in	
healthy	men	stimulated	gonadotropin	and	testosterone	secretion	sig-
nificantly	less	than	with	kisspeptin-	54	alone	and	had	no	effect	on	LH	
pulsatility.39	As	reductions	in	GnRH and Kiss1r	mRNA	were	observed	
after	administration	of	the	NKB	agonist	senktide	in	rats,40	it	was	pro-
posed	that	NKB	can	act	to	inhibit	GnRH	and	kisspeptin	transcription	
to	 reduce	 the	 stimulatory	action	of	 kisspeptin	on	gonadotrophins.39 
Gonadotropin	inhibitory	hormone	(GnIH)	also	appears	to	be	upstream	
of	kisspeptin,	having	no	suppressive	effect	on	kisspeptin-	induced	LH	
secretion	in	a	recent	study	in	men,41	although	its	interaction	with	neu-
rokinin	 B	 on	modulating	 GnRH	 secretion	 remains	 unknown.	Whilst	
it	 is	 possible	 that	NKB	exerts	variable	 stimulatory	 and/or	 inhibitory	
downstream	actions	on	kisspeptin	signalling,	perhaps	 in	response	to	
the	sex	steroid	 feedback	environment,	 the	present	data	clearly	sup-
port	a		stimulatory	role	of	NKB	signalling	in	the	normal	male	HPG	axis.
The	present	study	has	strengths	in	that	a	specific	neurokinin-	3	re-
ceptor	antagonist	was	used,	detailed	LH	pulse	profiling	was	performed	
with	blinded	pulse	analysis,	and	paired	data	were	obtained	for	the	con-
trol	period	and	during	administration	of	NK3R	antagonist.	The	lack	of	
suppression	in	the	frequency	of	LH	pulses	by	the	NK3R	antagonist	in	
men	is	in	contrast	to	the	same	dose	of	MLE4901	reducing	LH	pulse	
frequency	in	women	with	PCOS17	and	in	normal	women,23	which	may	
reflect	 sexual	dimorphism.	However,	 the	 sample	 size	 is	 small,	 and	a	
placebo	 control	 was	 not	 employed	 in	 this	 mechanistic	 exploratory	
study.
In	 summary,	we	 have	 shown	 that	NK3R	 antagonism	 resulted	 in	
suppression	of	both	LH	and	FSH	concentrations,	and	a	sustained	de-
crease	in	testosterone	secretion	in	healthy	men	over	a	7-	day	period,	
indicating	an	important	role	for	neurokinin	B	in	the	physiological	reg-
ulation	of	the	male	HPG	axis.	We	showed	that	the	NK3R	antagonist	
reduced	some	aspects	of	pulsatile	LH	secretion	 in	men.	Assessment	
of	the	interaction	between	neurokinin	B	and	kisspeptin	showed	that	
LH	response	to	kisspeptin	was	maintained	 in	the	presence	of	NK3R	
antagonist,	supporting	a	functionally	hierarchical	relationship	of	neu-
rokinin	B	being	predominantly	proximal	to	kisspeptin.	These	data	thus	
indicate	that	neurokinin	B	modulates	GnRH/LH	secretion	in	men,	with	
potential	 for	 therapeutic	 development	 as	well	 as	 exploration	 of	 its	
contribution	to	disorders	of	reproductive	function.
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